Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rowan T Chlebowski

Showing results (41-50 of 366) with videos related to

Pageof 37
Sort By:
Journal of the National Cancer Institute|September 11, 2008
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysisRowan T Chlebowski, Nananda Col
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonates and breast cancer preventionRowan T Chlebowski, Nananda Col
Journal of the National Cancer Institute|February 1, 2011
The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessmentRowan T Chlebowski, Garnet L Anderson
Journal of the National Cancer Institute|April 7, 2005
Progestins and recurrence in breast cancer survivorsRowan T Chlebowski, Garnet L Anderson
Annals of Internal Medicine|January 20, 2010
Hormone therapy suspension and mammography in Women's Health Initiative clinical trialsRowan T Chlebowski, Marcia L Stefanick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2016
Weight Loss Randomized Intervention Trials in Female Cancer SurvivorsRowan T Chlebowski, Marina M Reeves
Journal of the National Cancer Institute|March 20, 2012
Changing concepts: Menopausal hormone therapy and breast cancerRowan T Chlebowski, Garnet L Anderson
Menopause (New York, N.Y.)|August 14, 2008
Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer riskNananda F Col, Rowan T Chlebowski
Therapeutic Advances in Drug Safety|April 30, 2015
Menopausal hormone therapy and breast cancer mortality: clinical implicationsRowan T Chlebowski, Garnet L Anderson
Fertility and Sterility|October 22, 2003
HT and breast cancer riskMichelle L Geller, Rowan T Chlebowski
Pageof 37

Showing results (41-50 of 366) with videos related to

Sort By:
Pageof 37
Journal of the National Cancer Institute|September 11, 2008
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysisRowan T Chlebowski, Nananda Col
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonates and breast cancer preventionRowan T Chlebowski, Nananda Col
Journal of the National Cancer Institute|February 1, 2011
The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessmentRowan T Chlebowski, Garnet L Anderson
Journal of the National Cancer Institute|April 7, 2005
Progestins and recurrence in breast cancer survivorsRowan T Chlebowski, Garnet L Anderson
Annals of Internal Medicine|January 20, 2010
Hormone therapy suspension and mammography in Women's Health Initiative clinical trialsRowan T Chlebowski, Marcia L Stefanick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2016
Weight Loss Randomized Intervention Trials in Female Cancer SurvivorsRowan T Chlebowski, Marina M Reeves
Journal of the National Cancer Institute|March 20, 2012
Changing concepts: Menopausal hormone therapy and breast cancerRowan T Chlebowski, Garnet L Anderson
Menopause (New York, N.Y.)|August 14, 2008
Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer riskNananda F Col, Rowan T Chlebowski
Therapeutic Advances in Drug Safety|April 30, 2015
Menopausal hormone therapy and breast cancer mortality: clinical implicationsRowan T Chlebowski, Garnet L Anderson
Fertility and Sterility|October 22, 2003
HT and breast cancer riskMichelle L Geller, Rowan T Chlebowski
Pageof 37